摘要
目的：观察比较雷莫司琼崩解片与盐酸托烷司琼治疗含顺铂或蒽环类方案化疗所致恶心呕吐的疗效及不良反应。方法：将45例接受含顺铂或蒽环类方案化疗的患者随机分为AB、BA组。AB组第1周期静脉用盐酸托烷司琼；第2周期以雷莫司琼崩解片口服代替盐酸托烷司琼。BA组第1周期以雷莫司琼崩解片治疗；第2周期静脉用盐酸托烷司琼治疗。结果：可评价疗效的39例患者中，含雷莫司琼崩解片止呕方案和含盐酸托烷司琼止呕方案对急性恶心的有效率分别为89．7％和94．9％，迟发性恶心有效率分别为66．7％-82．1％和79．5％-89．7％。对急性呕吐的有效率分别为89．7％和92．3％，迟发性呕吐分别为87．2％-89．7％和84．6％-89．7％。两组疗效差异均无统计学上意义。两组不良反应亦无显著性差异。结论：雷莫司琼崩解片与盐酸托烷司琼在控制急性、迟发性恶心呕吐的有效率和毒副反应均相近，高效低毒，值得临床推广应用。
To study the efficacy and safety of ramosetron orally disintegrating tablet in preventing the nausea and vomiting induced by chemotherapy including cisplatin or doxorubicin, as comparison with domestic tropisetron bydrochloride. Methods ： All 45 eligible patients randomized into AB or BA group. In the group AB, domestic tropisetron hydrochloride combined with dexamethesone, metoclopramide and benadryl was given in the first cycle while domestic tropisetron hydrochloride was displaced by ramosetron orally disintegrating tablet in the second cycle. Those in BA group were given these drugs in the reverse order. Results： There were 39 patients who were achieved the assessment of clinical response. The control rate of acute nausea, delay nausea, acute wmiting and delay vomiting was 89.7% vs. 94.9%, 66.7%-82.1% vs. 79.5%-89.7%, 89.7% vs. 92.3% and 87.2%-89.7% vs. 84. 6%-89.7% , respectively（ P 〉 0. 05 ）. Conclusion：Ramosetron orally disintegrating tablet can effectively prevent the acute or delayed nausea and vomiting induced by chemotherapeutic agents, the effective and side effects are similar to those of domestic tropisetron hydrochloride.
出处
《临床肿瘤学杂志》
CAS
2009年第1期59-62,共4页
Chinese Clinical Oncology
关键词
雷莫司琼
托烷司琼
化学治疗
不良反应
恶心
呕吐
Ramosetron
Tropisetron hydrochloride
Chemotherapy
Adverse effects
Nausea
Vomiting
